Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-PRO: Bevacizumab, Pemetrexed, Cisplatin, or Erlotinib for Advanced NSCLC
NCT01116219Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2010
- Primary completion
- Jul 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started Jun 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT01116219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116219.